901.65
-0.85%
Geojit BNP Paribas
The quarter saw good product mix as well as strong project execution which aided the CDMO segment performance. In the formulation business, 6 ANDAs have already been approved, out of which 5 have been commercialized including one during Q3FY21. With a strong order book and customer base in the CDMO segment as well as increasing revenue from the formulation segment, the company is poised to sustain its growth momentum in the long term. Hence, we upgrade our rating from Accumulate to Buy with a rolled...
Promoters have increased holdings from 50.10% to 66.41% in Jun 2025 qtr.
More from Cohance Lifesciences Ltd.
Recommended